About the Company
United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $UTHR News
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo. This press release features ...
United Therapeutics gets grant for apparatus for pancreatic function restoration using membrane with cell systems
Discover United Therapeutics Corp's innovative patent for a blood purification apparatus with vascular and filtration channels. Learn about a groundbreaking method to restore pancreatic function.
United Therapeutics Corporation (UTHR)
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its ...
United Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform Rating
United Therapeutics (UTHR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
United Therapeutics Corp UTHR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
United Therapeutics Reports First Successful Xenothymokidney Transplant
By Chris Wack United Therapeutics reported the world's first successful transplant of a UThymoKidney, which the company produced, into a living person ...
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United StatesTORONTO and HOUSTON, April 26, 2024 (GLOBE ...
United Therapeutics Announces World's First Successful Xenothymokidney Transplant
The transplant is the third xenotransplant using United Therapeutics’ xeno organs, following two successful UHeart™ transplants at the University of Maryland Medicine in 2022 and 2023.
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
A) Genetically modified source pig, 16 to 20 weeks old. B) The thymus is then explanted from the source genetically modified ...
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful ...
Loading the latest forecasts...